Clinical Trial Update: Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether CYP2C19 genotype-guided antiplatelet therapy changes platelet reactivity in patients with coronary artery disease, including ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome
• Spontaneous Coronary Artery Dissection

Snippet

Sponsor: Nur Hafizah Annezah binti Utuh | Conditions: Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome) | Phase 4 | Status: NOT_YET_RECRUITING